Autolus Therapeutics (NASDAQ:AUTL) Sets New 12-Month Low – Here’s Why

Autolus Therapeutics plc (NASDAQ:AUTL) reached a new 52-week low on Wednesday . The stock traded as low as $2.85 and last traded at $2.86, with a volume of 131760 shares. The stock had previously closed at $2.95.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AUTL. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Friday, November 15th. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $7.00 to $7.60 in a research report on Monday. Finally, Needham & Company LLC reissued a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $10.15.

Autolus Therapeutics Price Performance

The company’s 50-day moving average price is $3.83 and its 200-day moving average price is $3.96. The company has a market cap of $754.37 million, a P/E ratio of -2.35 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter last year, the company earned ($0.26) EPS. On average, equities research analysts predict that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics in the second quarter valued at $43,000. Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics in the third quarter valued at $51,000. Daiwa Securities Group Inc. lifted its stake in Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after acquiring an additional 15,293 shares during the last quarter. Herbst Group LLC acquired a new stake in Autolus Therapeutics in the third quarter valued at $91,000. Finally, Bayesian Capital Management LP acquired a new stake in Autolus Therapeutics in the first quarter valued at $100,000. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.